NCT04637555View on ClinicalTrials.gov

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 26, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions
Post Myocardial Infarction
Interventions
DRUG

sacubitril/valsartan

LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY